About Us
Our Company
Management & Board
Aceragen
Tilsotolimod
Toll-Like Receptor Activation
Publications & Presentations
Investor Relations
×
Design Considerations for Clinical Trials Using the Cutaneous Dermatomyositis Disease Area and Severity Index as a Primary Endpoint
